Product Center
The first and only fully dosed, fully population-coverage quadrivalent influenza virus subunit vaccine in China has been approved for market
- Categories:Company news
- Author:
- Origin:
- Time of issue:2025-09-03
- Views:
(Summary description)Recently, Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") achieved a significant milestone—the supplementary application for its new Class I drug, the tetravalent influenza virus subunit vaccine ( HRK-X®), was approved by the National Medical Products Administration (NMPA) of China. The approved population now includes infants aged 6 to 35 months, making it the first and only tetravalent influenza virus subunit vaccine approved for the full population and full dosage in China. This advancement provides a safer and higher-quality new option for influenza prevention and control in the country, further aiding Ab&B Bio in expanding its market presence and making greater contributions to strengthening public health defenses and safeguarding public health.
The first and only fully dosed, fully population-coverage quadrivalent influenza virus subunit vaccine in China has been approved for market
(Summary description)Recently, Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") achieved a significant milestone—the supplementary application for its new Class I drug, the tetravalent influenza virus subunit vaccine ( HRK-X®), was approved by the National Medical Products Administration (NMPA) of China. The approved population now includes infants aged 6 to 35 months, making it the first and only tetravalent influenza virus subunit vaccine approved for the full population and full dosage in China. This advancement provides a safer and higher-quality new option for influenza prevention and control in the country, further aiding Ab&B Bio in expanding its market presence and making greater contributions to strengthening public health defenses and safeguarding public health.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2025-09-03 08:54
- Views:
Recently, Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") achieved a significant milestone—the supplementary application for its new Class I drug, the tetravalent influenza virus subunit vaccine ( HRK-X®), was approved by the National Medical Products Administration (NMPA) of China. The approved population now includes infants aged 6 to 35 months, making it the first and only tetravalent influenza virus subunit vaccine approved for the full population and full dosage in China. This advancement provides a safer and higher-quality new option for influenza prevention and control in the country, further aiding Ab&B Bio in expanding its market presence and making greater contributions to strengthening public health defenses and safeguarding public health.
Source: State Drug Administration Government Service Portal Website
Currently, the influenza virus remains one of the significant respiratory pathogens threatening public health. Seasonal flu outbreaks, sporadic cross-species transmission of influenza viruses, and pandemics have profound impacts on human health and socio-economics. Particularly for infants, the elderly, and patients with underlying cardiopulmonary conditions, infection with the influenza virus may lead to severe complications such as pneumonia, resulting in critical illness or death. At present, vaccination against influenza is the most effective measure to prevent the disease and its large-scale outbreaks.
The approval of the marketing application for the quadrivalent influenza virus subunit vaccine for children aged 6-35 months marks another significant milestone in Ab&B Bio's subunit influenza vaccine family. This high-quality vaccine, featuring high purity, low reactogenicity, excellent safety, and comprehensive protection, aligns with global vaccine development trends. It unifies the vaccine formulation for all individuals aged 6 months and above, greatly enhancing the convenience of administration and management, while providing broader population coverage, greater peace of mind, and more effective immune protection for influenza prevention and control in China.
Relevant information
-
Deepening Strategic Synergy to Jointly Strengthen Public Health Defense: Chongqing Center for Disease Control and Prevention (Chongqing Institute of Preventive Medicine) visited Ab&B Bio for a visit and exchange session.On August 5, 2026, a delegation comprising leaders and experts from the Chongqing Center for Disease Control and Prevention (Chongqing Institute of Preventive Medicine) visited Ab&B Bio-Tech CO.,LTD.JS to conduct an on-site inspection and hold a symposium. During the meeting, both parties engaged in in-depth discussions on topics such as innovative vaccine R&D, clinical evaluation, joint construction of technical platforms, sharing of data resources, talent cultivation, and technology commercialization, thereby accelerating the transition of their strategic cooperation from "paper-based consensus" to "substantive implementation." - The world's first! The monkeypox mRNA vaccine has obtained dual clinical trial approvals from both China and the United States. 07-02
- Phase I/II Clinical Trial of the Re engineered Respiratory Syncytial Virus Vaccine (CHO Cells)(Adjuvant)Officially Launched 05-13
- The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating. 05-08
- Our innovative vaccine research team won the 20th "Jiangsu Youth May Fourth Medal Collective" award 04-27
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
